NCT00570336

Study of CTS-1027 in Hepatitis C Patients

A Dose Response Study of CTS-1027 in Hepatitis C Patients

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 87 (actual)
• Sponsor: Conatus Pharmaceuticals Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if CTS-1027 can lower elevated liver enzymes in patients with chronic HCV infection.

Detailed description

Randomized, placebo-controlled, double-blind, parallel group, multicenter, dose response trial utilizing four doses of CTS-1027, administered orally once daily, in outpatients with chronic hepatitis C virus (HCV) infection.

Conditions

• Chronic Hepatitis C Virus Infection

Interventions

Type	Name	Description
DRUG	CTS-1027	Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd (quaque die, once daily).
OTHER	Placebo	Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd.

Timeline

• Start date: 2007-12-01
• Primary completion: 2009-07-01
• Completion: 2009-07-01
• First posted: 2007-12-10
• Last updated: 2010-09-16

Locations

19 sites across 1 country: United States